Comparative Pharmacology
Head-to-head clinical analysis: ANESTACON versus BENOXINATE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANESTACON versus BENOXINATE HYDROCHLORIDE.
ANESTACON vs BENOXINATE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Local anesthetic that stabilizes the neuronal membrane by inhibiting sodium ion influx, thereby blocking nerve impulse conduction.
Sodium channel blocker; stabilizes neuronal membrane and prevents initiation and transmission of nerve impulses.
5% lidocaine ointment, apply topically 3-4 times daily as needed; maximum single dose 20 g of ointment (1 g lidocaine), maximum total daily dose 60 g (3 g lidocaine).
1-2 drops of 0.4% solution in the conjunctival sac up to every 5-10 minutes for surface anesthesia, not exceeding 7 doses per procedure.
None Documented
None Documented
Terminal elimination half-life is 1.5–2.5 hours; clinically relevant for dosing interval.
2.5-3.5 minutes in plasma; extremely short half-life due to rapid hydrolysis by plasma esterases, limiting systemic exposure after ocular administration
Renal (90% as unchanged drug and metabolites; 10% fecal/biliary).
Primarily renal; approximately 70-80% excreted unchanged in urine; minor biliary/fecal elimination (<10%)
Category C
Category C
Topical Anesthetic
Topical Anesthetic